Answer
Jun 22, 2026 - 02:42 PM
The success rate of encorafenib depends on the condition being treated and is often measured by overall response rate (ORR) or progression-free survival (PFS) in clinical trials. For example, in combination with binimetinib for BRAF-mutant metastatic melanoma, encorafenib has shown an ORR of around 63% and a median PFS of about 14.9 months. Success rates may vary in different cancers and when used as monotherapy or in combination.
